NervGen Pharma (NGEN) Stock Price, News & Analysis

Company Overview

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings. NervGen’s development activities center on progressing NVG-291 and related research through clinical trials to assess safety, tolerability and potential to improve functional outcomes for patients with neurological damage.

NervGen is publicly traded on the NASDAQ under the ticker NGEN and operates as a research-driven biopharmaceutical organization. The company conducts clinical development activities and research collaborations to support its programs and to advance regulatory development pathways for its therapeutics.

As a clinical-stage company, NervGen’s prospects are tied to the progress and results of its clinical trials and development partnerships. Its work is representative of the broader effort in biotechnology to develop novel regenerative treatments for conditions with significant unmet medical need in neurology. Investors and stakeholders typically follow clinical milestones and regulatory updates when evaluating the company’s progress.

Key Stats

• Today's Range: $2.16 to $2.25
• 50-Day Range: $1.59 to $2.34
• 52-Week Range: $1.58 to $6.30
• Volume: 8,697 shs
• Average Volume: 503,437 shs
• Market Capitalization: $174.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Moderate Buy

NervGen Pharma Stock Analysis - MarketRank™

NervGen Pharma scored higher than 50% of companies evaluated by MarketBeat, and ranked 571st out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NervGen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NervGen Pharma has a consensus price target of $14.00, representing about 533.5% upside from its current price of $2.21.

Amount of Analyst Coverage

NervGen Pharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for NervGen Pharma are expected to decrease in the coming year, from ($0.40) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NervGen Pharma is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NervGen Pharma is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NervGen Pharma has a P/B Ratio of 73.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.62% of the float of NervGen Pharma has been sold short.

Short Interest Ratio / Days to Cover

NervGen Pharma has a short interest ratio ("days to cover") of 13.83, which indicates bearish sentiment.

Change versus previous month

Short interest in NervGen Pharma has recently decreased by 1.87%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NervGen Pharma does not currently pay a dividend.

Dividend Growth

NervGen Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.08

News Sentiment

NervGen Pharma has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for NervGen Pharma this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for NGEN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

9 people have added NervGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NervGen Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

NervGen Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/01/2026
• Status update: 9/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NGEN
• CIK: 1751912
• Web: nervgen.com
• Phone: (604) 722-5361
• Fax: N/A
• Employees: N/A
• Year Founded: 2017

Price Target and Rating

• Average Price Target for NervGen Pharma: $14.00
• High Price Target: $18.00
• Low Price Target: $10.00
• Potential Upside/Downside: +533.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,259.82%
• Return on Assets: -199.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 73.67

Miscellaneous

• Outstanding Shares: 80,630,000
• Free Float: N/A
• Market Cap: $178.19 million
• Optionable: N/A
• Beta: N/A